Advertisement

TheBodyPRO.com Covers CROI 2017

News

World Health Organization Pediatric Dosing Tool

April 2017

A pediatric dosing tool developed by World Health Organization (WHO) might assist in the design of clinical trials for dosing in children.

When finding a safe and effective dose for children, the approach in anti-infectives is to target drug exposures similar to those in successfully treated adults. Scaling pharmacokinetics (PK) is the first step.

Down to two or three years of age, body size accounts for most of the differences in doses between children and adults.

The pediatric dosing tool -- developed by the WHO pediatric ARV Working Group (PAWG) -- uses allometric scaling to help evaluate antiretroviral dosing regimens. The WHO pediatric dosing tool was presented at CROI 2017.

Advertisement

Allometric scaling describes the nonlinear effect of body size on PK parameters. A milligram per kilogram (mg/kg) dose in children and adults causes under-dosing in children. Even without other available information, allometry is a better guess than constant mg/kg. But pediatric dosing regimens still use constant mg/kg dosing as first best guess.

The objective of the work by the PAWG is to bridge this gap. WHO proposes an easy-to-use tool to assist researchers not familiar with PK modelling to design and evaluate pediatric dosing regimens.

The tool operates in Microsoft Excel and has easy steps to follow with results displayed in real time. It uses allometric scaling to adjust for the effect of a child's body size on clearance and it targets the same area under the time-concentration curve (AUC) as that for adults. The lowest and highest values within a pediatric weight band are shown alongside the target.

The tool can also analyse multiple drugs in a fixed dose combination and used either standarised or customised weight bands. If the effect of maturation is known for a drug this can be specified.

The WHO group note that allometric scaling alone only works well down to two years of age. Below that immature organ function could mean that clearance might be lower than that predicted using only body size. This is specific to individual drugs. Other unaccounted for factors might also have an impact: lower protein binding in children; drug formulation differences; and poor absorption.

Another limitation is that terminal half-life is usually shorter in children so adult AUC targets might lead to higher Cmax and lower Cmin so it might be necessary to dose smaller children twice daily.

The group stress that the tool is to support the design of clinical trials for dosing in pediatrics and is "not a substitute for confirmatory studies". They add that the use of the tool in study design "would represent a significant step away from the constant mg/kg paradigm, possibly leading to improvements in the efficacy of pediatric dosing trials".


Reference

Denti P et al. An easy-to-use pediatric dosing tool: one mg/kg dose does not fit all. CROI 2017, 13-17 February 2017, Seattle. Poster abstract 809.
www.croiconference.org/sessions/easy-use-paediatric-dosing-tool-one-mgkg-dose-does-not-fit-all (Abstract and poster)


Related Stories

Tenofovir Alafenamide Exposure Is Modestly Higher in Children Than Adults
Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants



Visit HIV i-Base's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.